Detail of "14689-45-3"

Reference

Selection of quantum dot wavelengths for biomedical assays and imaging

Selection of quantum dot wavelengths for biomedical assays and imaging.Several substances are used for example 14689-45-3 and 4731-53-7 which are their cas registry numbers. Lim, Yong Taik; Kim, Sungjee; Nakayama, Akira; Stott, Nathan E.; Bawendi, Moungi G.; Frangioni, John V. (Beth Israel Deaconess Medical Center, Boston, MA 02215, USA). Molecular Imaging, 2(1), 50-64 (English) 2003 MIT Press. CODEN: MIOMBP. ISSN: 1535-3508. DOCUMENT TYPE: Journal CA Section: 9 (Biochemical Methods) Section cross-reference(s): 13 Fluorescent semiconductor nanocrystals (quantum dots [QDs]) are hypothesized to be excellent contrast agents for biomedical assays and imaging. A unique property of QDs is that their absorbance increases with increasing sepn. between excitation and emission wavelengths. Much of the enthusiasm for using QDs in vivo stems from this property, since photon yield should be proportional to the integral of the broadband absorption. In this study, we demonstrate that tissue scatter and absorbance can sometimes offset increasing QD absorption at bluer wavelengths, and counteract this potential advantage. By using a previously validated math. model, we explored the effects of tissue absorbance, tissue scatter, wavelength dependence of the scatter, water-to- Hb ratio, and tissue thickness on QD performance. We conclude that when embedded in biol. fluids and tissues, QD excitation wavelengths will often be quite constrained, and that excitation and emission wavelengths should be selected carefully based on the particular application. Based on our results, we produced near-IR QDs optimized for imaging surface vasculature with white light excitation and a silicon CCD camera, and used them to image the coronary vasculature in vivo. Taken together, our data should prove useful in designing fluorescent QD contrast agents optimized for specific biomedical applications. .

Polyurethanes and their preparation

Polyurethanes and their preparation. Simpson, Scott S. (Rogers Corp., USA). Ger. 14689-45-3 and 12084-29-6 are also occured in this study. Offen. DE 19626007 A1 23 Jan 1997, 14 pp. (German). (Germany). CODEN: GWXXBX. CLASS: ICM: C08G018-22. ICS: C08G018-10. ICA: C08G018-76; C08G018-79; C08G018-48; C08G018-42; C08G018-66; C07C049-92; C07C049-14; B01J031-12. ICI: C08G018-22, C08G101-00. APPLICATION: DE 1996-19626007 27 Jun 1996. PRIORITY: US 1995-504855 20 Jul 1995. DOCUMENT TYPE: Patent CA Section: 37 (Plastics Manufacture and Processing) Polyurethane foams are prepd. using 31 metal acetylacetonate and acetylacetone in which a urethane mixt. and catalyst is heated to a temp. at which the acetylacetone inhibitor is driven off and the formation of polyurethane is accelerated. This method provides control of the catalyst at higher temps. suitable for foam processing. In an example, a foam was prepd. from Arco 34-45, UC 0200, dipropylene glycol, and Isonate 143L using Fe(III) acetylacetonate and acetylacetone. .